<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01207752</url>
  </required_header>
  <id_info>
    <org_study_id>SCCO 10-6</org_study_id>
    <nct_id>NCT01207752</nct_id>
  </id_info>
  <brief_title>The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction</brief_title>
  <official_title>Evaluation of the Efficacy of an Ocular Emulsion on the Signs and Symptoms of Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California College of Optometry at Marshall B. Ketchum University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California College of Optometry at Marshall B. Ketchum University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study will be to determine the efficacy of this novel, lipid-containing&#xD;
      artificial tear on the signs and symptoms of meibomian gland disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear Film Breakup Time</measure>
    <time_frame>Measured 2 hours after in-office administration of a single drop of test solution</time_frame>
    <description>time in seconds to observer a dark spot in the tear film</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Systane Balance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artificial tear emulsion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optive Lubricant Eye Drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artificial tear</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systane Balance</intervention_name>
    <description>Artificial tear emulsion drop</description>
    <arm_group_label>Systane Balance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optive Lubricant Eye Drops</intervention_name>
    <description>Artificial tear eye drop</description>
    <arm_group_label>Optive Lubricant Eye Drops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Schein symptom score (all 6 questions) of greater than 5,&#xD;
&#xD;
          -  evidence of MGD changes in both eyes (i.e.,&#xD;
&#xD;
          -  lower eyelid secretion quality score greater than 1.0 (0 - 3 scale) OR gland dropout&#xD;
             score greater than 1.0 (i.e., greater than 25% of entire lower eyelid) as demonstrated&#xD;
             by meiboscopy, and corneal staining of grade 4.0 or greater (0 - 20 scale).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contact lens wear, use of topical ocular medication other than artificial tears (use&#xD;
             of Restasis is specifically excluded),&#xD;
&#xD;
          -  unstable systemic medication use (i.e., anti-histamines, steroids, etc.), recent&#xD;
             (within 6 months of study start) ocular trauma or surgery,&#xD;
&#xD;
          -  diabetes, aqueous deficient dry eye (defined as a Schirmer I value (without&#xD;
             anesthetic) of &lt; 5 mm of wetting in 5 minutes in either eye), and use of punctal&#xD;
             plugs.&#xD;
&#xD;
        -Subjects taking omega 3 fatty acid supplements for dry eye can be included so long as&#xD;
        their intake is stable for the prior six months and they meet the inclusion criteria above.&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry R Paugh, OD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern California College of Optometry at Marshall B. Ketchum University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Care Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 21, 2010</study_first_submitted>
  <study_first_submitted_qc>September 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2010</study_first_posted>
  <results_first_submitted>January 26, 2016</results_first_submitted>
  <results_first_submitted_qc>March 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2021</results_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern California College of Optometry at Marshall B. Ketchum University</investigator_affiliation>
    <investigator_full_name>Jerry R. Paugh, OD, PhD</investigator_full_name>
    <investigator_title>Professor, Associate Dean for Research</investigator_title>
  </responsible_party>
  <keyword>dry eye, meibomian gland dysfunction, tear film break up time</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Systane Balance</title>
          <description>Artificial tear emulsion&#xD;
Systane Balance: Artificial tear emulsion drop</description>
        </group>
        <group group_id="P2">
          <title>Optive Lubricant Eye Drops</title>
          <description>Artificial tear&#xD;
Optive Lubricant Eye Drops: Artificial tear eye drop</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Systane Balance</title>
          <description>Artificial tear emulsion&#xD;
Systane Balance: Artificial tear emulsion drop</description>
        </group>
        <group group_id="B2">
          <title>Optive Lubricant Eye Drops</title>
          <description>Artificial tear&#xD;
Optive Lubricant Eye Drops: Artificial tear eye drop</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="17.7"/>
                    <measurement group_id="B2" value="54.7" spread="17.5"/>
                    <measurement group_id="B3" value="52.7" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tear Film Breakup Time</title>
        <description>time in seconds to observer a dark spot in the tear film</description>
        <time_frame>Measured 2 hours after in-office administration of a single drop of test solution</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Systane Balance</title>
            <description>Artificial tear emulsion&#xD;
Systane Balance: Artificial tear emulsion drop</description>
          </group>
          <group group_id="O2">
            <title>Optive Lubricant Eye Drops</title>
            <description>Artificial tear&#xD;
Optive Lubricant Eye Drops: Artificial tear eye drop</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Film Breakup Time</title>
          <description>time in seconds to observer a dark spot in the tear film</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" spread="1.73"/>
                    <measurement group_id="O2" value="4.42" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.550</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Systane Balance</title>
          <description>Artificial tear emulsion&#xD;
Systane Balance: Artificial tear emulsion drop</description>
        </group>
        <group group_id="E2">
          <title>Optive Lubricant Eye Drops</title>
          <description>Artificial tear&#xD;
Optive Lubricant Eye Drops: Artificial tear eye drop</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jerry Paugh, OD, PhD</name_or_title>
      <organization>Southern California College of Optometry at MBKU</organization>
      <phone>714-449-7487</phone>
      <email>jpaugh@ketchum.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

